Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

TRANSFORMATIVE NON-INVASIVE CAUSAL MECHANOSTICS PLATFORM TO EFFECTIVELY TRIAGE AND TREAT ENDOMETRIOSIS

Project description

A better tool endometriosis diagnosis

An estimated 200 million women and girls worldwide suffer from endometriosis, experiencing symptoms such as menstruation pain, heavy menstrual bleeding, and chronic pelvic pain. Like other chronic conditions, endometriosis is also difficult to diagnose and treat. Laparoscopy is currently the only method for diagnosing the disease. The EIC-funded TRANSCEND project aims to introduce a new diagnostic tool that can predict disease risk based on its underlying causes. This tool is non-invasive and does not require surgery. The project aims to enable earlier diagnosis, provide more personal care, and enhance the quality of life.

Objective

Complex chronic diseases like endometriosis consume 80% of Europe’s healthcare budget. Endometriosis is a painful condition in which the lining of the uterus grows outside the uterus. It affects 200 million women worldwide at the peak of their productive and reproductive years and costs Europe €70bn/year.

As with other complex chronic diseases, endometriosis results from multiple combinations of genetic, clinical and environmental factors, making it difficult to diagnose and treat. On average it takes 8 years to diagnose, typically involving 10+ medical consultations. The current diagnostic standard is laparoscopy - an invasive, expensive and painful surgery.

Neither non-invasive, accurate early-diagnostic tools nor effective treatments currently exist for endometriosis. As many as 60% of endometriosis cases are undiagnosed. As such, a pressing medical need exists for an affordable and scalable precision diagnostic solution to guide personalised treatments.

Building on successful results from our Horizon 2020 FEMaLe project, this EIC Accelerator project will clinically validate the world’s first accurate, cost-effective, scalable and simple to use diagnostic test to predict an individual's risk of developing endometriosis based on the underlying causal mechanisms of the disease. Using these novel insights, this project will demonstrate how the diagnostic can be used to target clinically repurposed drugs to successfully treat specific disease subtypes.

Having identified critical disease signatures and potential drug candidates to repurpose (TRL6 achieved), EIC support is essential to certify our novel diagnostic as a Class C IVDR device and prove the efficacy of repurposed drugs to treat endometriosis for a €4bn global market.

Overcoming these remaining risky and challenging barriers will enable us to achieve €251m in revenues, €171m in net profits and grow our highly skilled team to 73 FTEs by Y5 post-project, thereby realising our full commercial potential.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC - HORIZON EIC Accelerator

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02

See all projects funded under this call

Coordinator

PRECISIONLIFE LTD
Net EU contribution
€ 2 136 005,34
Address
UNIT 8B BANKSIDE, HANBOROUGH BUSINESS PARK, LONG HANBOROUGH
OX29 8LJ Witney
United Kingdom
SME
Yes
Region
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data

Participants (2)